Today before the opening
bell, Advaxis announced that it will be presenting at the 16th Annual BIO CEO
& Investor Conference at the Waldorf Astoria in New York City in
mid-February. Mr. Daniel J. O’Connor, Chief Executive Officer of Advaxis, will
be presenting a company update at the conference on Tuesday, February 11, 2014
at 3:30 pm EST.
Those who wish to see the
presentation are advised to visit the following link for a live webcast:
http://www.veracast.com/webcasts/bio/ceoinvestor2014/08238316629.cfm.
Advaxis is a clinical-stage
biotechnology company developing the next generation of cancer immunotherapies.
Advaxis’ immunotherapies are based on a novel platform technology using live,
attenuated bacteria to stimulate the immune system to selectively target cancer
cells while reducing tumor defenses.
For more information, visit:
www.advaxis.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
